[
1. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89-103. DOI: 10.5114/pg.2018.8107210.5114/pg.2018.81072679113431616522
]Search in Google Scholar
[
2. Campos FG. Colorectal cancer in young adults: A difficult challenge. World J Gastroenterol. 2017;23(28):5041-5044. DOI: 10.3748/wjg.v23. i28.504110.3748/wjg.v23.i28.5041
]Search in Google Scholar
[
3. Connell LC, Mota JM, Braghiroli MI, Hoff PM. The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment. Curr Treat Options Oncol. 2017;18(4):23. DOI: 10.1007/s11864-017-0463-310.1007/s11864-017-0463-328391421
]Search in Google Scholar
[
4. Mármol I, Sánchez-de-Diego C, Pradilla DA, Cerrada E, Rodriguez Yoldi MJ. Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. Int J Mol Sci. 2017;18(1):197. DOI: 10.3390/ ijms1801019710.3390/ijms18010197529782828106826
]Search in Google Scholar
[
5. Recio-Boiles A, Cagir B. Colon Cancer. [Updated 2021 Jan 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470380/
]Search in Google Scholar
[
6. Maffeis V, NicolèL, Cappellesso R. RAS, cellular plasticity, and tumor budding in colorectal cancer. FronOncol. 2019;9;1255. DOI: 10.3389/fonc.2019.0125510.3389/fonc.2019.01255687775331803624
]Search in Google Scholar
[
7. Buday L, Downward J. Many faces of Ras activation. Biochimica et Biophysica Acta. 2008;1786(2):178-87. DOI: 10.1016/j.bbcan.2008.05.00110.1016/j.bbcan.2008.05.00118541156
]Search in Google Scholar
[
8. Takács T, Kudlik G, Kurilla A, Szeder B, Buday L, Vas V. The effects of mutant Ras proteins on the cell signalome. Cancer Metastasis Rev. 2020;39:1051-65. DOI: 10.1007/s10555-020-09912-810.1007/s10555-020-09912-8768033732648136
]Search in Google Scholar
[
9. Hwang K, Yoon JH, Lee JH, Lee S. Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers Biomedicines. 2021; 9(1):39. DOI: 10.3390/biomedicines901003910.3390/biomedicines9010039782481633466394
]Search in Google Scholar
[
10. Porebska I, Harlozińska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol. 2000;21(2):105-15. DOI: 10.1159/00003011610.1159/00003011610686540
]Search in Google Scholar
[
11. Dassonville O, Bozec A, Fischel JL, Milano G. EGFR targeting therapies: Monoclonal antibodies versus tyro-sine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol. 2007;62:53-61. DOI: 10.1016/j. critrevonc.2006.12.00810.1016/j.critrevonc.2006.12.008
]Search in Google Scholar
[
12. Porru M, Pompili L, Caruso C, Biroccio A, Leonetti C. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. J Exp Clin Cancer Res. 2018;37(1):57. DOI: 10.1186/s13046-018-0719-110.1186/s13046-018-0719-1585091329534749
]Search in Google Scholar
[
13. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemo-therapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304(16):1812-20. DOI: 10.1001/jama.2010.153510.1001/jama.2010.153520978259
]Search in Google Scholar
[
14. BankovicLazarević D, Krivokapić Z, Barišić G, Jovanović V, Ilić D, Veljković M. Organized colorectal cancer screening in Serbia - the first round within 2013-2014. Vojnosanit Pregl. 2016;73:360-7. DOI: 10.2298/ VSP150421113B10.2298/VSP150421113B29309104
]Search in Google Scholar
[
15. Vekic B, Dragojevic-Simic V, Jakovljevic M, Pilipovic F, Simic R, Zivic R, et al. Medical cost of colorectal cancer services in Serbia between 2014 and 2017: National data report. Front Pharmacol. 2019;10:526. DOI: 10.3389/fphar.2019.0052610.3389/fphar.2019.00526653040531156439
]Search in Google Scholar
[
16. Patel A, Tripathi G, Gopalakrishnan K, Williams N, Arasaradnam RP. Field cancerisation in colorectal cancer: a new frontier or pastures past? World J Gastroenterol. 2015;21(13):3763-72. DOI: 10.3748/wjg.v21. i13.376310.3748/wjg.v21.i13.3763
]Search in Google Scholar
[
17. Lea IA, Jackson MA, Li X, Bailey S, Peddada SD and Dunnick JK. Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns. Carcinogenesis. 2007;28:1851-8. DOI: 10.1093/carcin/ bgm17610.1093/carcin/bgm176
]Search in Google Scholar
[
18. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials. Ann Oncol. 2015;26:13-21. DOI: 10.1093/annonc/mdu37810.1093/annonc/mdu37825115304
]Search in Google Scholar
[
19. Garcia-Carbonero N, Martinez-Useros J, Li W, Orta A, Perez N, Carames C, et al. KRAS and BRAF mutations as prognostic and predictive biomarkers for standard chemotherapy response in metastatic colorectal cancer: A single institutional study. Cells 2020;9(1):219. DOI: 10.3390/cells901021910.3390/cells9010219701663431952366
]Search in Google Scholar
[
20. Bruera G, Cannita K, Di Giacomo D, Lamy A, FrébourgT, Sabourin JS, et al. Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemo-therapy plus bevacizumab (FIr-B/FOx). BMC Med. 2013;11:59. DOI: 10.1186/1741-7015-11-5910.1186/1741-7015-11-59363586923497191
]Search in Google Scholar
[
21. Jones RP, Sutton PA, Evans JP, Clifford R, McAvoy A, Lewis J, et al. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br J Cancer. 2017;116(7):923-9. DOI: 10.1038/bjc.2017.3710.1038/bjc.2017.37537914928208157
]Search in Google Scholar
[
22. Sirisena ND, Deen K, Mandawala DEN, Herath P, Dissanayake VHW. The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka. BMC Research Notes. 2017;10(1):392. DOI: 10.1186/s13104-017-2731-510.1186/s13104-017-2731-5555360628797274
]Search in Google Scholar
[
23. SadoughA, Afshari M, Rostami F, Berzegari S, Janbabaee G, Tabrizi R, et al. A systematic review and meta-analysis on the prevalence of KRAS gene mutation in samples of colorectal cancer. WCRJ. 2020;7:e1522.
]Search in Google Scholar
[
24. Jakovljevic K, Malisic E, Cavic M, Krivokuca A, Dobricic J, Jankovic R. KRAS and BRAF mutations in Serbian patients with colorectal cancer. J BUON. 2012;17(3):575-80.
]Search in Google Scholar
[
25. Jankovic R, Brotto K, MalisicE,Krivokuca A, Cavic M, Jovanovic K, Boljevic I, Tanic M, Radulovic S. KRAS mutations in colorectal cancer patients in Serbia: 5 years experience of central testing. Ann Oncol. 2014;25 (Supplement 2): ii14-ii104.
]Search in Google Scholar
[
26. Awidi M, Ababneh N, Shomaf M, AlFararjeh F, Owaidi L, Al Khatib M, et al. KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan. PloS One. 2019;14(12):e0226473. DOI: 10.1371/journal.pone.022647310.1371/journal.pone.0226473693428831881025
]Search in Google Scholar
[
27. Korphaisarn K, Pongpaibul A, Roothumnong E,Pong-suktavorn K, Thamlikitkul L, Anekpuritanang T, et al. High frequency of KRAS codon 146 and FBXW7 mutations in Thai patients with stage II-III colon cancer. Asian Pac J CancerPrev. 2019;20(8):2319-26. DOI: 10.31557/APJCP.2019.20.8.231910.31557/APJCP.2019.20.8.2319685281931450901
]Search in Google Scholar
[
28. Xie MZ, Li JL, Cai ZM, Li KZ, Hu BL. Impact of primary colorectal cancer location on the KRAS status and its prognostic value. BMC Gastroenterol. 2019;19(1):46. DOI: 10.1186/s12876-019-0965-510.1186/s12876-019-0965-5643798530917791
]Search in Google Scholar
[
29. Bylsma LC, Gillezeau C, GarawinTA,Kelsh MA, Fryzek JP, Sangare L, Lowe KA.Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer Med. 2020;9(3):1044-57. DOI: 10.1002/cam4.274710.1002/cam4.2747699709531856410
]Search in Google Scholar
[
30. Baran B, OzupekNM, Tetik NY, Acar E, Bekcioglu O, Baskin Y. Difference between left-sided and right-sided colorectal cancer: a focused review of literature. Gastroenterology Res. 2018;11:264-73. DOI: 10.14740/ gr1062w10.14740/gr1062w608958730116425
]Search in Google Scholar
[
31. Dai D, Wang Y, Zhu L, Jin H, Wang X. Prognostic value of KRAS mutation status in colorectal cancer patients: a population-based competing risk analysis. Peer J. 2020;8:e9149. DOI: 10.7717/peerj.914910.7717/peerj.9149727188732547859
]Search in Google Scholar
[
32. Li W, Qiu T, Zhi W, Shi S, Zou S, Ling Y, Shan L, Ying J, Lu N. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages BMC Cancer. 2015;15:340. DOI: 10.1186/ s12885-015-1345-310.1186/s12885-015-1345-3442310725929517
]Search in Google Scholar
[
33. Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD. Biochemical and structural analysis of common cancer-associated KRAS mutations. MolCancer Res. 2015;13:1325-35. DOI: 10.1158/1541-7786.MCR-15-020310.1158/1541-7786.MCR-15-020326037647
]Search in Google Scholar
[
34. Mu-oz-Maldonado C, Zimmer Y, Medová M. A Comparative Analysis of Individual RAS Mutations in Cancer Biology. Front Oncol. 2019;18;9:1088. DOI: 10.3389/fonc.2019.0108810.3389/fonc.2019.01088681320031681616
]Search in Google Scholar
[
35. Fiala O, Buchler T, Mohelnikova-Duchonova B, Melichar B, Matejka VM, Holubec L, Kulhankova J, Bortlicek Z, Bartouskova M, Liska V, Topolcan O, Sedivcova M, Finek J. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumour Biol. 2016;37(5):6823-30. DOI: 10.1007/s13277-015-4523-710.1007/s13277-015-4523-726662311
]Search in Google Scholar